Geographic atrophy (GA), secondary to age-related macular degeneration (AMD), remains one of the most challenging conditions ...

SAN DIEGO — The investigational drug pegcetacoplan, a C3/C3b inhibitor, showed significant benefits in the treatment of patients with C3 glomerulopathy or primary immune complex–mediated ...

Patients with paroxysmal nocturnal hemoglobinuria (PNH) who had suboptimal response to eculizumab can switch to pegcetacoplan for a cost-effective alternative, according to. acost analysis.

SEATTLE, Washington — Treatment with pegcetacoplan (Syfovre, Apellis Pharmaceuticals) produced clinically meaningful reductions in the growth of geographic atrophy (GA) lesions through month 30, ...

Developing meds for amyotrophic lateral sclerosis (ALS) is challenging under the best of circumstances. Now, Apellis Pharmaceuticals has run into a setback for its candidate. Friday, Mizuho Securities ...

A rare and life-threatening kidney disease in children finally has an effective therapy, thanks in large part to pioneering research and clinical leadership from University of Iowa Health Care Stead ...

Pegcetacoplan treatment led to proteinuria reduction and eGFR stabilization across important subgroups with C3 glomerulopathy and IC-MPGN. Pegcetacoplan induces a clinically meaningful ...

Please provide your email address to receive an email when new articles are posted on . Pegcetacoplan was associated with a 68.3% reduction in proteinuria at 26 weeks vs. placebo. Of patients treated ...

A cost-utility analysis conducted from the perspective of the Italian health system found that pegcetacoplan was more effective and less costly than 2 complement 5 (C5) inhibitors for the treatment of ...

No new safety signals were observed New data presented at late-breaking session at the European Renal Association Congress Marketing applications for EMPAVELI are under review with the FDA and EMA In ...

Please provide your email address to receive an email when new articles are posted on . Pegcetacoplan reduced proteinuria in patients with rare complement-mediated glomerular diseases vs. placebo.

The Nature Index 2026 Research Leaders reveal the leading institutions and countries/territories in the natural sciences, health sciences, applied sciences and social sciences, according to their ...